Immucell Corp.
- ICCC ยท Nasdaq
- In Vitro & In Vivo Diagnostic Substances
- Portland, ME
- 73 employees
- CIK 0000811641
Updated from SEC filings through
Top things to know
Executives
- Boekhorst Paul Francis Olivier te President and CEO 4, 2026-06-22
- chief financial officer chief financial officer 10-K, 2026-03-30
-
Bobbi Jo Brockmann VP of Sales and Marketing 4, 2026-04-14
What leadership is saying
“Total sales for the three months ended September 30, 2026 were $8.0 million, a 46.0% increase compared to the three months ended September 30, 2025. Domestic sales were $6.9 million, a 29.2% increase compared to 2025”
Earnings press release (8-K Ex. 99.1), filed October 13, 2026
Immucell Corp is a U.S. public company in in vitro & in vivo diagnostic substances (SIC 2835), headquartered in Portland, ME. It trades as ICCC on Nasdaq. Revenue was $27.6M in the fiscal year ending December 31, 2025, +4.3% from the year before. It reported about 73 employees. Boekhorst Paul Francis Olivier te is President and CEO.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $27.6M 10-K, 2026-03-30 | $26.5M 10-K, 2025-03-28 | $17.5M 10-K, 2025-03-28 | $18.6M 10-K, 2024-04-01 | $19.2M 10-Q, 2023-11-13 |
| Operating income | $1.6M 10-K, 2026-03-30 | -$1.6M 10-K, 2026-03-30 | -$5.7M 10-K, 2025-03-28 | -$2.3M 10-Q, 2024-11-13 | $257K 10-Q, 2023-11-13 |
| SG&A | $6.8M 10-K, 2026-03-30 | $5.7M 10-K, 2026-03-30 | $5.2M 10-K, 2025-03-28 | $5.5M 10-Q, 2024-11-13 | $4.2M 10-Q, 2023-11-13 |
| Net income | -$1.0M 10-K, 2026-03-30 | -$2.2M 10-K, 2026-03-30 | -$5.8M 10-K, 2025-03-28 | -$2.5M 10-K, 2024-04-01 | -$78K 10-K, 2023-03-29 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Boekhorst Paul Francis Olivier te | President and CEO | 4, 2026-06-22 |
| Michael F. Brigham | Board member (per proxy) bio: Former President, Chief Executive Officer, Treasurer and Secretary | DEF 14A, 2026-04-24 |
| PAUL OLIVIER TE BOEKHORST | Board member (per proxy) bio: President, Chief Executive Officer, and Director | DEF 14A, 2026-04-24 |
| chief financial officer | chief financial officer | 10-K, 2026-03-30 |
| Bobbi Jo Brockmann | VP of Sales and Marketing | 4, 2026-04-14 |
| ANTHONY A. DIMARCO | Board member (per proxy) bio: Director | DEF 14A, 2026-04-24 |
| DAVID S. TOMSCHE, D.V.M. | Board member (per proxy) bio: Director | DEF 14A, 2026-04-24 |
| GILLES GUILLEMETTE | Board member (per proxy) bio: Director | DEF 14A, 2026-04-24 |
| KATHY V. TURNER | Board member (per proxy) bio: Director | DEF 14A, 2026-04-24 |
| PAUL R. WAINMAN | Board member (per proxy) bio: Director | DEF 14A, 2026-04-24 |
What Immucell Corp does
ImmuCell Corporation, founded in 1982 and a SEC-registered public company since 1987, is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. The Company's practical, science-based solutions help prevent calf scours, one of the most prevalent diseases in neonatal calves worldwide that accounts for 30-40% of pre-weaning mortality in many production systems.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 9.1 million (as of July 31, 2026) | 10-Q, August 13, 2026 |
|---|---|---|
| Public float | $50.6M (as of June 27, 2025) | 10-K/A, May 13, 2026 |
| Reportable segments | 2 (period ending June 30, 2026) | 10-Q, August 13, 2026 |
| Latest proxy statement | Meeting June 11, 2026 (filed April 24, 2026) | DEF 14A, April 24, 2026 |
| Auditor | Wipfli LLP (Radnor, Pennsylvania) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| June 18, 2026 | Boekhorst Paul Francis Olivier te President and CEO | Buy | 8,000 | $76K | Form 4, June 22, 2026 |
| December 3, 2025 | Boekhorst Paul Francis Olivier te President and CEO | Buy | 9,785 | $49K | Form 4, December 3, 2025 |
| November 25, 2025 | David Scott Tomsche Director | Buy | 3,266 | $16K | Form 4, November 28, 2025 |
Recent 8-K events
- 8-K filed 2026-10-13
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-13
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-09
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-17
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-06-10
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-05-14
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-08
- Item 1.01 Entry into a material definitive agreement
- 8-K filed 2026-04-14
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 8.01 Other events
- 8-K filed 2026-04-08
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-18
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about Immucell Corp
- What does Immucell Corp do?
- In its own words, from Item 1 of its 10-K: "ImmuCell Corporation, founded in 1982 and a SEC-registered public company since 1987, is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. The Company's practical, science-based solutions help prevent calf scours, one of the most prevalent diseases in neonatal calves worldwide that accounts for 30-40% of pre-weaning mortality in many production systems."
- What is Immucell Corp's revenue?
- $27.6M for the fiscal year ending December 31, 2025, from its 10-K filed March 30, 2026.
- Is Immucell Corp profitable?
- Immucell Corp reported net income of -$1.0M for the fiscal year ending December 31, 2025.
- How many employees does Immucell Corp have?
- About 73 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Immucell Corp?
- Boekhorst Paul Francis Olivier te, President and CEO, as named in a 4 filed June 22, 2026.
- Who is the CFO of Immucell Corp?
- chief financial officer, chief financial officer, as named in a 10-K filed March 30, 2026.
- Where is Immucell Corp headquartered?
- Portland, ME.
- What is Immucell Corp's stock ticker?
- ICCC on Nasdaq.
- What industry is Immucell Corp in?
- In Vitro & In Vivo Diagnostic Substances, SIC code 2835.
- What is Immucell Corp's website?
- immucell.com.
- When does Immucell Corp report earnings next?
- November 13, 2026 at 09:00. Source: sec_8k.
- Is Immucell Corp a public company?
- Yes. Immucell Corp files with the SEC under CIK 0000811641 and trades as ICCC.
- Who audits Immucell Corp?
- Wipfli LLP, Radnor, Pennsylvania, as named in its latest annual report (10-K).
- How many shares of Immucell Corp are outstanding?
- 9.1 million shares as of July 31, 2026, from its 10-Q filed August 13, 2026.
- What is Immucell Corp's public float?
- $50.6M as of June 27, 2025, as reported on the cover of its 10-K/A filed May 13, 2026.
- How many business segments does Immucell Corp report?
- 2 reportable segments for the period ending June 30, 2026, from its 10-Q filed August 13, 2026.
- When is Immucell Corp's annual shareholder meeting?
- June 11, 2026, per its proxy statement (DEF 14A) filed April 24, 2026.
- Have Immucell Corp insiders traded stock recently?
- Since November 25, 2025, officers and directors reported 0 open-market sales and 3 purchases worth about $140K on Forms 4 and 5. The most recent: Boekhorst Paul Francis Olivier te (President and CEO) bought 8,000 shares on June 18, 2026.